Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has provided an update.
Recordati has published key documents for its upcoming ordinary and extraordinary shareholders’ meeting scheduled for 29 April 2026, making them available at its registered office, on its website and via an authorised storage mechanism. The materials include the 2026 remuneration policy and 2025 compensation report, directors’ reports on the new 2026–2028 Performance Shares Plan, authorisation to buy and sell treasury shares, and a proposed delegation of powers to the Board under the Italian Civil Code, highlighting governance, incentive and capital management issues that shareholders will be asked to approve.
The most recent analyst rating on (IT:REC) stock is a Buy with a EUR57.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. is an international pharmaceutical group listed on Borsa Italiana, offering therapies in both general and specialist medicine as well as in rare diseases. The company operates an integrated model from clinical development to production, commercialisation and licensing of active pharmaceutical ingredients and finished products across about 150 countries in EMEA, the Americas and APAC.
Average Trading Volume: 357,584
Technical Sentiment Signal: Buy
Current Market Cap: €10B
Learn more about REC stock on TipRanks’ Stock Analysis page.